Summary
Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’ novel treatments to patients. PRA Health Sciences is diligently working to meet our clients’ data demands through the substantial growth of our Data Monitoring Committee (DMC) services over recent years. Staffed by a global team of experts, PRA’s dedicated DMC Unit ensures our clients’ projects meet the most stringent regulatory requirements.
Register to download
Data Monitoring Committee Unit
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Poster
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
White Paper
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…